Condition: VEXAS · VEXAS Syndrome · Sponsor: Swedish Orphan Biovitrum
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
This description comes directly from the study's public registry record.
Study Physician · +4686972000 · medical.info@sobi.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Scottsdale | Scottsdale, Arizona, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Cleveland Clinic - Cleveland | Cleveland, Ohio, United States | Recruiting |
| The James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
| UT MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Utah Healthcare | Salt Lake City, Utah, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| Vancouver Coastal Health Research Institute | Vancouver, British Columbia, Canada | Recruiting |
| Queen Elizabeth II Health Sciences Center | Halifax, Nova Scotia, Canada | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06782373